A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.

Trial Details

NCT ID
NCT05327647
Phase
PHASE2
Sponsor
CHU de Quebec-Universite Laval
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Bicalutamide
  • Control Arm
Locations (sample)
  • London, Ontario, Canada|42.98339,-81.23304
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Lévis, Quebec, Canada|46.80326,-71.17793
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Males, age 18 or greater.
  • Patients with histologically confirmed non-muscle invasive urothelial carcinoma.
  • Patients have been recommended for a course of intravesical BCG induction treatment by their urologist
  • Patients who received gemcitabine, epirubicin or mitomycin C instillations immediately post-operatively will be eligible for enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →